# US 2025/0154130 A1 · Novel thr beta analogs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154130 A1
- Document ID: US20250154130A1
- Status: Published application
- Kind: A1
- Application number: 18/837,378
- Filed: 2023-02-10
- Published: 2025-05-15
- Earliest claimed: 2022-02-10
- Assignees: Madrigal Pharmaceuticals, Inc.
- Applicants: Madrigal Pharmaceuticals, Inc.
- Inventors: JAMES K. HENNAN; PASQUALE N. CONFALONE
- Web page: https://patentgrep.com/patent/US20250154130A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are compounds of formula I: and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, and their uses as thyroid hormone receptor (THR) β activators.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R1 is independently halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-10 carbocyclyl, or C6-14 aryl;
each R2 is independently halogen, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R3 is halogen, —CN, —NO2, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, —SRb, —S(═O)Ra, —S(═O)2Ra, —S(═O)2ORb, —S(═O)2NRcRd, —NRcRd, —NRcS(═O)2Ra, —NRcS(═O)2Ra, —NRcS(═O)2ORb, —NRcS(═O)2NRcRd, —RbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —ORb, —OS(═O)2Ra, —OS(═O)2ORb, —OS(═O)2NRcRd, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —C(═O)Ra, —C(═O)ORb, or —C(═O)NRcRd, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru;
each occurrence of R4 and R6 is independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, or 3- to 10-membered heterocyclyl, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru;
each R5 is independently halogen, —CN, —NO2, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, —SRb, —S(═O)Ra, —S(═O)2Ra, —S(═O)2ORb, —S(═O)2NRcRd, —NRcRd, —NRcS(═O)2Ra, —NRcS(═O)2Ra, —NRcS(═O)2ORb, —NRcS(═O)2NRcRd, —NbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —ORb, —OS(═O)2Ra, —OS(═O)2ORb, —OS(═O)2NRcRd, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —C(═O)Ra, —C(═O)ORb, or —C(═O)NRcRd, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru;
m is an integer selected from 0 to 4;
n is an integer selected from 0 to 2;
X is selected from —C(R7)2—, —O—, —NR8—, and —S—;
each R7 is independently hydrogen, halogen, —CN, —NO2, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, —SRb, —S(═O)Ra, —S(═O)2Ra, —S(═O)2ORb, —S(═O)2NRcRd, —NRcRd, —NRcS(═O)2Ra, —NRcS(═O)2Ra, —NRcS(═O)2ORb, —NRcS(═O)2NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —ORb, —OS(═O)2Ra, —OS(═O)2ORb, —OS(═O)2NRcRd, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —C(═O)Ra, —C(═O)ORb, or —C(═O)NRcRd, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more Ru; and
R8 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, or 3- to 10-membered heterocyclyl, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more Ru;
wherein:
each Ru is independently halogen, —CN, —NO2, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, —SRb, —S(═O)Ra, —S(═O)2Ra, —S(═O)2ORb, —S(═O)2NRcRd, —NRcRd, —NRcS(═O)2Ra, —NRcS(═O)2Ra, —NRcS(═O)2ORb, —NRcS(═O)2NRcRd, —NbC(═O)NRcRd, —NbC(═O)Ra, —NbC(═O)ORb, —ORb, —OS(═O)2Ra, —OS(═O)2ORb, —OS(═O)2NRcRd, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —C(═O)Ra, —C(═O)ORb, or —C(═O)NRcRd, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —OMe, —NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-6 alkyl, or C1-6 haloalkyl;
two Ru are taken together to form an oxo; or
two Ru, together with the one or more intervening atoms, form a C6-14 aryl, 5- to 14-membered heteroaryl, C3-10 carbocyclyl, or 3- to 10-membered heterocyclyl;
each Ra is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, C6-14 aryl, or 5- to 14-membered heteroaryl, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —OMe, —NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-6 alkyl, or C1-6 haloalkyl;
each Rb is independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, C6-14 aryl, or 5- to 14-membered heteroaryl, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —OMe, —NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-6 alkyl, or C1-6 haloalkyl; and
each Rc and Rd is independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 carbocyclyl, 3- to 10-membered heterocyclyl, C6-14 aryl, or 5- to 14-membered heteroaryl, wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —OMe, —NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-6 alkyl, or C1-6 haloalkyl;
or Rc, Rd, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl optionally substituted with one or more oxo, halogen, —CN, —OH, —OMe, —NH2, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C1-6 alkyl, or C1-6 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each R1 is independently halogen, C1-6 alkyl, C1-6 alkoxy, or C6-14 aryl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein m is 0, 1, or 2.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each R2 is independently halogen or C1-6 alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein each R2 is halogen.

### Claim 6 (depends on 1)

The compound of claim 1, wherein each R2 is chloride.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R3 is —CN, —C(═O)ORb, or —C(═O)NRcRd.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R3 is —CN.

### Claim 9 (depends on 1)

The compound of claim 1, wherein each Rc and Rc is H.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R3 is —C(═O)NH2.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Rb is H.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 is —C(═O)OH.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R4 is hydrogen.

### Claim 14 (depends on 1)

The compound of claim 1, wherein n is 0.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R6 is hydrogen.

### Claim 16 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is selected from the compounds described in Table I, and pharmaceutically acceptable salts, stereoisomers, and solvates thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A method of activating thyroid hormone receptor (THR) R in a patient or a biological sample, the method comprising contacting the patient or biological sample with a compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.

### Claim 20 (depends on 1)

A method of treating a liver disease or disorder, or a lipid disease or disorder, the method comprising administering to a patient in need thereof a compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the liver disease or disorder is nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or fatty liver disease.

### Claim 22 (depends on 20)

The method of claim 20, wherein the lipid disease or disorder is dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), or high low-density lipoprotein (LDL).

### Claim 23 (depends on 22)

The method of claim 22, wherein hypercholesterolemia is heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH).

### Claim at position 24

-31. (canceled)
